MUMBAI, India, July 7 -- Intellectual Property India has published a patent application (202641076643 A) filed by Dr. Sadhu Venkateswara Rao; and Vijaya Institute Of Pharmaceutical Sciences For Women on June 20, 2026, for Preparation And Characterization Of Controlled Release Chitosan Microspheres Encapsulating Mebeverine Hydrochloride.
Inventors include Dr. Sadhu Venkateswara Rao; Ms. P. Udaya Lakshmi; Ms. Sk. Heena; Ms. P. Swetha Sri; Ms. P. Lohitha Sri; and Ms. S. Vijaya Lakshmi.
The application for the patent was published on July 03, 2026, under issue no. 27/2026.
Abstract: ABSTRACT [0018] A novel controlled release chitosan microsphere system for Mebeverine Hydrochloride has been developed through ionic gelation technique to address the limitations of conventional dosage forms, such as short half-life and frequent dosing requirements for managing irritable bowel syndrome and related gastrointestinal disorders. This invention proposes an optimized microsphere delivery platform that encapsulates the antispasmodic drug within a biocompatible chitosan matrix cross-linked with sodium tripolyphosphate, enabling sustained drug release over an extended period while enhancing entrapment efficiency and therapeutic consistency. The formulation employs a systematic 2³ full factorial design to evaluate and optimize key formulation variables including chitosan concentration, cross-linking agent concentration, and stirring speed, resulting in microspheres with high yield, excellent flow properties, and particle sizes suitable for controlled delivery. Experimental outcomes demonstrated entrapment efficiencies ranging up to approximately 83.5% and sustained drug release profiles reaching around 82% over 12 hours in optimized batches, with stability confirmed under accelerated conditions. This approach offers improved patient compliance through reduced dosing frequency and maintains drug stability without significant degradation. The technology stands distinct by integrating process parameters like stirring speed alongside formulation factors in a full factorial optimization framework specifically tailored for Mebeverine Hydrochloride, providing a reproducible, solvent-minimized method with strong potential for scale-up in gastrointestinal therapeutics.
Disclaimer: Curated by HT Syndication.
